Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 13/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338771 | 1.00 | RIPK1 (0.43) | RIPK1HTR1AJAK2JAK1JAK3 | |
| SCHEMBL30338906 | 1.00 | RIPK1 (0.43) | RIPK1HTR1AJAK2JAK1JAK3 | |
| SCHEMBL25816985 | 1.00 | RIPK1 (0.43) | RIPK1HTR1AJAK2JAK1JAK3 | |
| SCHEMBL25257714 | 1.00 | RIPK1 (0.43) | RIPK1HTR1AJAK2JAK1JAK3 | |
| SCHEMBL30338823 | 1.00 | RIPK1 (0.43) | RIPK1HTR1AJAK2JAK1JAK3 | |
| SCHEMBL25297184 | 1.00 | RIPK1 (0.43) | RIPK1HTR1AJAK2JAK1JAK3 | |
| SCHEMBL30338558 | 1.00 | RIPK1 (0.43) | RIPK1HTR1AJAK2JAK1JAK3 | |
| SCHEMBL30338708 | 0.87 | RIPK1 (0.50) | RIPK1HTR1ADGAT2 | |
| SCHEMBL25816784 | 0.87 | RIPK1 (0.50) | RIPK1HTR1ADGAT2 | |
| SCHEMBL25816819 | 0.87 | RIPK1 (0.50) | RIPK1HTR1ADGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885HTR1A 2931/4885JAK2 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.